Physician profile
Carolyn M Lentzsch-Parcells
NPI 1366605735
$45,891.28
in general payments reported to CMS, 2019-2025
14 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $182 · 2021: $271 · 2022: $309 · 2023: $2,171 · 2024: $502 · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $5,726 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,795 · Food and Beverage: $2,606 · Consulting Fee: $1,850 · Honoraria: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,767.50 |
| Travel and Lodging | $5,725.88 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,795.00 |
| Food and Beverage | $2,605.60 |
| Consulting Fee | $1,850.00 |
| Honoraria | $1,230.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $36,841.03 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $5,081.94 | 2024-2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $2,176.72 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $748.61 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $394.51 | 2019-2025 | Dyanavel Xr, Quillivant |
| Corium, LLC | $337.27 | 2022-2025 | Azstarys |
| Stryker Corporation | $146.85 | 2020 | |
| Adlon Therapeutics L.P. | $35.59 | 2021 | |
| Noven Therapeutics, LLC | $33.46 | 2025 | Xelstrym, Secuado |
| Organon LLC | $27.40 | 2021-2022 | |
| Novo Nordisk INC | $19.62 | 2024 | Wegovy |
| Neos Therapeutics, Lp | $18.25 | 2025 | Cotempla Xr-Odt |
| Glaxosmithkline, LLC. | $17.37 | 2023 | Bexsero, Menveo, Pediarix |
| Merck Sharp & Dohme LLC | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Lentzsch-Parcells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.